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Abstract
Background
The PROMOTE study aims to measure long-term antiretroviral treatment (ART) safety and
adherence; compare HIV disease progression; assess subsequent adverse pregnancy out-
comes; evaluate effect of ART exposure on growth and development in HIV-exposed unin-
fected children; and assess long-term survival of mothers and children. This report primarily
describes cohort characteristics at baseline to better understand long-term outcomes.
Methods and findings
This is a prospective study. HIV-infected mothers and their children originally recruited in a
multisite randomized clinical trial for prevention of perinatal HIV transmission were re-enrolled
in PROMOTE. A total of 1987 mothers and 1784 children were enrolled from eight sites in
Uganda, Malawi, Zimbabwe and South Africa. Most women (�75%) reported being married
in Malawi and Zimbabwe compared to low proportions in South Africa (4.4% in Durban and
15% in Soweto), and 43.5% in Uganda (p<0.001). There were variabilities in contraceptive
practices: injectable contraceptive was the commonest reported method (40.9% overall);
implant was the second commonest (15.7% overall); oral contraceptives were common in
Zimbabwe; and tubal ligation was common in Malawi and South Africa. At baseline, 97.8% of
women reported currently using ART; 96.4% were in WHO clinical class 1 or 2; median CD4
cell count was 825 cells per uL; and viral load was undetectable in 1637 (~85%) of the
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women. Approximately, 14% of women did not inform their primary partners of their own HIV
status, 18% reported that they knew their partners were not HIV tested, and 9% did not know
if partner was tested. Overall mean age of children at enrollment was 3.5 years; and 5.7% and
25.0% had weight-for-age and height-for-age z-scores <2 standard deviations, respectively.
Conclusions
These baseline data show high adherence to ART use. However, issues of HIV disclosure
and reproductive intentions remain important. In addition to ART and ensuring high adher-
ence, other preventive measures should be included.
Introduction
The Promoting Maternal and Infant Survival Everywhere (PROMISE) multi-country random-
ized trial showed that perinatal HIV transmission can be reduced to ~0.5% when antiretroviral
treatment (ART) is used during pregnancy and likewise post-partum continuation of maternal
ART or infant prophylaxis can lead to very low rates of transmission during breastfeeding [1,
2]. Key agencies, including World Health Organization (WHO), now recommend use of life-
long ART regimens [3]. Based on the Population-based HIV Impact Assessment (PHIA) sur-
veys it appears that several African countries are making progress in increasing number of
individuals being HIV tested, initiating ART, and achieving high levels of viral suppression [4].
Therefore, major achievements have been made in reduction of HIV transmission, slower
HIV disease progression and improved health as a result of viral suppression and improved
immunological status. Nonetheless, the expanding use of ART across the life span requires
long-term monitoring to assess safety and durability–especially among women and children as
newer regimens are introduced. The importance of safety monitoring in reproductive age
women is demonstrated by recent reports from Botswana where switching to dolutegravir has
raised concerns of potential association of dolutegravir with adverse reproductive outcomes
[5, 6]. In multiple settings in Sub-Saharan Africa, fertility remains high and subsequent preg-
nancies are common among HIV-infected women. Despite huge reductions in perinatal HIV
transmission, the roll-out of ART has resulted in millions of HIV-exposed, uninfected infants
and children, being exposed to approximately 30 months of ART. This includes both in utero
from as early as conception through up to 18–24 months of breastfeeding during a period of
rapid brain and somatic physical growth. Unfortunately, most ART drugs have limited
research safety data on dosing and safety in pregnant or breastfeeding women and in children.
This includes pregnancy outcomes and later pediatric growth and development [7]. WHO rec-
ommends toxicity and pregnancy outcome surveillance be conducted to provide safety infor-
mation on ART regimens. This is particularly important in low-resource settings where
malnutrition and other comorbidities are prevalent [8].
The PEPFAR PROMise Ongoing Treatment Evaluation (PROMOTE) study has been imple-
mented to provide long-term follow-up data on safety outcomes of widespread use of ART
among an already well-characterized cohort of HIV infected mothers and their children who
previously enrolled in the multi-site PROMISE study [1]. The major specific aims of the PRO-
MOTE study are to longitudinally evaluate adherence to ART and durability of consistent
ART use among postpartum women; assess safety of long-term use of ART, including alterna-
tive regimens among women who initiated ART or switched use of ART during the PROMISE
study from enrollment to end of follow-up postpartum; compare HIV disease progression by
The PROMOTE antiretroviral treatment study baseline findings
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regimen and HIV-subtype; assess subsequent adverse pregnancy outcomes by regimen; and
assess maternal and infant health outcomes to document the impact of long-term treatment.
In this manuscript, we describe the PROMOTE study design, baseline data on women and
children who enrolled in PROMOTE (originally enrolled in PROMISE), and discuss the signif-
icance of the study. These analyses primarily focus on baseline enrollment data to assist in
understanding the long-term outcomes of the PROMOTE study.
Materials and methods
Design
The PROMOTE study is an observational study to prospectively follow mothers and children
who were originally recruited in the multi-country PROMISE randomized trial [1]. The PRO-
MOTE enrollment started in December 2016—after termination and close-out of the PROM-
ISE trial in 2015 (Fig 1). PROMOTE enrollment was completed in June 2017 and follow-up is
planned to continue up to 2021.
Setting and study populations
The PROMOTE study is conducted at eight research sites in four African countries: Makerere
University Johns Hopkins University (MUJHU)/Kampala (Uganda), Blantyre and Lilongwe
(Malawi), Harare, Seke North and St. Mary’s (Zimbabwe), Perinatal Health Research Unit
(PHRU)/Johannesburg and uMlazi/Durban (South Africa). Fig 1 shows the study cohorts and
the timing of their enrollment: 1) HIV-infected women who previously enrolled in the PROM-
ISE trial from the eight African sites are enrolled and followed in the PROMOTE study; 2) The
first born infants in PROMISE are enrolled in PROMOTE and followed with their mothers; 3)
All children born during the PROMOTE follow-up as a result of a subsequent (repeat) preg-
nancy are enrolled and followed with their mothers. In addition to these distinct three cohorts,
Fig 1. PROMOTE Study populations, enrollment and follow-up.
https://doi.org/10.1371/journal.pone.0208805.g001
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a small group of infants were born after closure of the PROMISE study and prior to start of the
PROMOTE study. These “Gap” children were not formally enrolled; however, mothers were
interviewed at PROMOTE baseline about the date of birth and survival status of these children.
Inclusion criteria
Women and children enrolled in the PROMISE trial (and children born subsequently in PRO-
MOTE) from one of eight African sites in Uganda, Malawi, Zimbabwe and South Africa;
mothers willing to provide informed consent to enroll and continue follow-up in the PRO-
MOTE study for herself and for her children); lives within the study catchment area; and has
no plans to move during the study period. If a mother died, a caregiver can sign the informed
consent to continue follow-up of the child who enrolled originally in PROMISE. If the child
died, the mother can consent to be followed without her child.
Exclusion criteria
Mother not able or willing to provide informed consent to continue follow-up in the PRO-
MOTE study; plans to relocate permanently out of the catchment area during the cohort study
period; judged by the site team and protocol chairs as having social or other reasons which
would make it difficult for the mother/child pair to comply with study requirements.
Study procedures for mothers
HIV-infected women previously enrolled in the PROMISE study were enrolled after appropri-
ate counseling and consenting in the PROMOTE study. New study visits, schedule of evalua-
tions, procedures, and study forms were implemented. The maternal screening and
enrollment evaluations included: eligibility evaluations (e.g., obtaining written informed con-
sent to participate in follow-up and collection of study samples), administration of sociodemo-
graphic questionnaires, medical history, physical examinations (e.g., WHO clinical staging
and comorbid conditions such as TB), and provision of ART adherence counseling. ART is
supplied per national guidelines as the prevailing standard of care in each country (efavirenz
[EFV]-based regimen in Malawi, Zimbabwe and South Africa, and protease inhibitor [PI]-
based regimen in Uganda). Enrollment laboratory evaluations included: complete blood count
(CBC) with differential, CD4+ cell count, viral load, and serum chemistries (alanine amino-
transferase, creatinine and creatinine clearance). Additional procedures included dual-energy
X-ray absorptiometry (DXA scan), and storage of samples (blood samples for resistance testing
and hair for cumulative drug levels). The maternal follow-up evaluations are conducted every
six months and include: medical history, physical examination, adherence questionnaire (and
counseling), and child neurodevelopmental questionnaire (every 12 months). Participants are
allowed to attend interim visits for health conditions or issues pertaining to ART. Women
who miss their scheduled visit during a certain window period or with abnormal laboratory
results (e.g., high viral load) are actively followed at the location they provided and advised to
return to the clinic for follow-up. Transportation costs are provided for follow-up visits. Data
are collected at scheduled and interim visits as appropriate. The laboratory follow-up proce-
dures were similar to the enrollment procedures. Women who enrolled in PROMOTE and
subsequently had a repeat pregnancy followed a specific initial schedule that included preg-
nancy registration, confirmation of pregnancy, medical history and physical examination, and
laboratory tests which included hepatitis B surface antigen test. Antenatal (monthly) and deliv-
ery evaluations and laboratory tests were also conducted similar to enrollment visits. At all
scheduled and unscheduled visits evaluation of adverse events and classification was based on
the DAIDS toxicity table (Version 2 [9]).
The PROMOTE antiretroviral treatment study baseline findings
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Study procedures for children
Two cohorts of children are part of the PROMOTE study: those born during the PROMISE
trial and those born subsequently during the PROMOTE study. The enrollment evaluations for
Children born in the PROMISE trial included eligibility evaluations, clinical evaluations (medi-
cal history, physical examination [including neurological], documentation of the child’s HIV
status, survival status and anthropometric measures). The enrollment evaluations also included
laboratory tests (CBC with differential, HIV status), DXA scan, developmental testing, and Dis-
ability/ Child Behavior questionnaires. Follow-up evaluations for first born PROMISE and
repeat pregnancy children included clinical and laboratory evaluations every 6 months.
Data management
The PROMOTE study is managed by a Coordinating Center at the Johns Hopkins University
in Baltimore, Maryland, and data management and statistical support is provided by a Data
Management Center (DMC) at the Centre for the AIDS Programme of Research in South
Africa (CAPRISA) in Durban, South Africa. PROMOTE study data are completed on desig-
nated case report forms (CRFs) by trained study workers. At the outset, research teams at all
sites received training on the protocol, manual of operations, and quality control (QC)/quality
assurance (QA) procedures. Regular monitoring of the study is provided by two designated
scientists. Data QC/QA is conducted at the clinical sites, data are entered locally, and securely
transferred to the DMC in South Africa. The DMC monitors site data entry of CRFs, data
completion and provides refresher training whenever needed. A unique data sharing feature of
the PROMOTE study is use of the same participant identification as in the PROMISE random-
ized clinical trial to allow data access from time of birth of the first child in PROMISE provid-
ing a follow-up opportunity of approximately 11 years for mothers and children from time of
enrollment in PROMISE to completion of PROMOTE (this plan has been approved and
included in the consent form).
Statistical analyses
For the baseline data included in this report, we present descriptive and stratified analyses by
research site and country. Current analyses are restricted to summaries of enrolled cohorts of
women and children, and description of factors related to socioeconomic, reproductive, ART,
and adverse events at the time of enrollment (baseline). Even though site specific data will be
presented, data for few selected variables (marital status, socioeconomic status indicated by
availability of water and electricity, travel time to the clinic, HIV status disclosure and CD4 cell
count) were included by country for statistical testing purposes. Fisher-Freeman-Halton test
and Kruskal-Wallis test were used to determine if there was an association between countries
and few selected categorical and continuous variables, respectively.
Study approval and provision of clinical care
The PROMOTE study was approved by all relevant institutional review boards (IRBs) in the
U.S. and collaborating African research sites/countries. These are: MUJHU/Kampala, Uganda:
The Joint Clinical Research Centre (JCRC) IRB in Uganda and The Johns Hopkins Medical
Institutions (JHMI) IRB in the U.S.; Blantyre, Malawi: College of Medicine Research and Eth-
ics Committee (COMREC) in Malawi and Johns Hopkins Medical Institutions (JHMI) IRB in
the U.S.; Lilongwe, Malawi: National Health Sciences Research Committee (NHSRC) in
Malawi and University of North Carolina, Chapel Hill (UNC-CH) Office of Human Research
Ethics IRB in the U.S.; Harare, Seke North and St. Mary’s sites, Zimbabwe: Medical Research
The PROMOTE antiretroviral treatment study baseline findings
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Council of Zimbabwe (MRCZ) National Ethics Committee; PHRU, Johannesburg, South
Africa: University of Witwatersrand Human Research Ethics Committee (Medical); and
uMlazi, Durban, South Africa: Biomedical Research Ethics Committee and Kwazulu-Natal
Department of Health. All women signed a written informed consent form to enroll and be
followed with their children for the duration of the study and to provide study samples. All
women are on ART regimens provided as the standard of care in each country. The PRO-
MOTE study provides at no cost laboratory testing and clinical management as necessary.
Children found HIV-infected are started on ART per country-specific regimens and guide-
lines. Maternal counseling on antiretroviral adherence and other health issues are also pro-
vided at the clinics.
Results
Overall, 1987 mothers and 1784 children were enrolled in PROMOTE from the PROMISE
study (Table 1). Additionally, 134 children were born and enrolled during PROMOTE follow-
up for a total of 3905 women and children (Table 1). Approximately, 340 children not first
born in PROMISE (“Gap” children) were born to PROMISE mothers before entry into the
PROMOTE study and not formally enrolled. The number of new pregnancies in PROMOTE
to the time of this analysis and the outcomes of these pregnancies are also shown in Table 1.
Selected baseline characteristics of the 1784 children enrolled in PROMOTE from the
PROMISE study are shown in Table 2. The overall mean age was 3.5 years. The overall propor-
tions of children with weight-for-age and height-for-age z-scores <2 standard deviations
(SDs) were 5.7% and 25.0%, respectively (with wide variabilities across sites).
Table 3 shows maternal sociodemographic characteristics by site and country. Most of the
characteristics were comparable across sites. In particular, there were substantial and
Table 1. PROMOTE enrollment by country and research site.
Country Uganda Malawi Zimbabwe South Africa
Research Site MUJHU-Kampala Blantyre Lilongwe Harare Seke
North
St. Mary’s PHRU-Soweto uMlazi-
Durban
Total
Cohort 1: HIV-infected mothers 352 343 322 94 179 175 273 249 1987
Cohort 2: First born children in PROMISE 310 317 289 91 169 162 244 202 1784
Cohort 3: PROMOTE children
(subsequent pregnancies at time of
analysis)
27 35 24 4 13 13 15 3 134
All children 337 352 313 95 182 175 259 205 1918
Total mothers and children enrolled 689 695 635 189 361 350 532 454 3905
PROMOTE pregnancies
New pregnancies at time of analyses 64 49 45 11 29 29 42 15 284
Number with pregnancy outcomes 27 31 24 4 14 14 19 3 136
Pregnancy outcomes, n (%)
Live birth 24 (88.9%) 30
(96.8%)
20
(83.3%)
2
(50.0%)
13
(92.9%)
14
(100.0%)
15 (78.9%) 3 (100.0%) 121
(89.0%)
Low birth weight <2500g 1 (3.7%) 0 2 (8.3%) 1
(25.0%)
0 0 1 (5.3%) 0 5 (3.7%)
Preterm delivery <37 weeks 1 (3.7%) 0 1 (4.2%) 0 0 0 0 0 2 (1.5%)
Stillbirth/Intrauterine fetal death >_20
weeks
0 1 (3.2%) 0 0 1 (7.1%) 0 1 (5.3%) 0 3 (2.2%)
Abortion/miscarriage <20weeks 0 0 1 (4.2%) 1
(25.0%)
0 0 2 (10.5%) 0 4 (2.9%)
Congenital anomalies 1 (3.7%) 0 0 0 0 0 0 0 1 (0.7%)
https://doi.org/10.1371/journal.pone.0208805.t001
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statistically significant differences among countries by marital status (p<0.001), socioeco-
nomic status (indicated by availability of electricity (p<0.001) and water in the living premises
(p<0.001)), and travel time to the study clinic (p<0.001). For example, most women (75% or
more) reported being married in Malawi and Zimbabwe compared to very low rates in South
Africa (4.4% in Durban and 15% in Soweto), and 43.5% in Uganda. Although overall, 30.4% of
the women reported 1 hour or more of travel time to access the specific study clinic, there was
a wide variability– 58.0% in Uganda, 36.6%-39.9% in Malawi, and much less in Zimbabwe and
South Africa. Table 3 also shows maternal nutritional status based on body mass index (BMI)
assessment (kg/m2). The overall frequency of being underweight (BMI <18.5) was 4.1%; the
sites in Blantyre, Malawi and Seke North, Zimbabwe showed highest frequencies (9.0% and
6.1%, respectively).
Table 5 shows maternal baseline ART information by research site and country. Overall,
97.8% of women reported currently taking ART at enrollment in PROMOTE study; the rates
were uniformly high at all sites and only 43 (2.2%) women were not using ART. Few (3.5%)
women were in WHO clinical class 3 or 4. The overall median CD4 cell count at baseline was
high: 825.5 cells per uL with minimal variability between sites within the same country. How-
ever, the differences in CD4 count (cells per uL) among countries were statistically significant
(Uganda: 963.5; Malawi: 739; Zimbabwe: 911.5; South Africa: 794; p<0.001). The viral load
(VL) detectability using various cutoff points is shown in Table 5. Overall, VL was not detect-
able in 1628 (~85%) of the women. Of the 292 women with detectable VL, in 77 women VL
was�200 copies/mL, in 17 women VL was 200–399 copies/mL, in 32 women VL was 400–
Table 2. Baseline characteristics of children enrollment in PROMOTE study.
Uganda Malawi Zimbabwe South Africa
MUJHU-Kampala
(N = 310)
Blantyre
(N = 317)
Lilongwe
(N = 289)
Harare
(N = 91)
Seke North
(N = 169)
St. Mary’s
(N = 162)
PHRU-Soweto
(N = 244)
uMlazi-
Durban
(N = 202)
Total
(N = 1784)
First born children in
PROMISE
Gender, n (%) (N = 1781)
Male 161 (52.1%) 164
(51.7%)
156
(54.0%)
41 (45.1%) 88 (52.1%) 84
(51.9%)
123 (50.6%) 98 (48.8%) 915
(51.4%)
Female 148 (47.9%) 153
(48.3%)
133
(46.0%)
50 (54.9%) 81 (47.9%) 78
(48.1%)
120 (49.4%) 103 (51.2%) 866
(48.6%)
Children age–years,
Mean (SD)�
3.6 (1.0) 3.3 (1.0) 3.7 (0.9) 3.6 (1.1) 3.6 (0.9) 3.4 (1.1) 3.5 (1.0) 3.7 (1.0) 3.5 (1.0)
Anthropometrics
Weight-for-age (N = 1775)
Mean z-score -0.50 -0.91 -0.71 -0.71 -0.43 -0.51 -0.25 -0.08 -0.53
SD� for z-score 0.86 0.87 0.97 0.88 0.87 0.94 1.09 0.96 0.97
Proportion below 3 SD� 1 (0.3%) 6 (1.9%) 3 (1.0%) 1 (1.1%) 1 (0.6%) 0 1 (0.4%) 0 13 (0.7%)
Proportion below 2 SD� 10 (3.2%) 30 (9.5%) 28 (9.8%) 6 (6.6%) 3 (1.8%) 9 (5.6%) 11 (4.5%) 5 (2.5%) 102 (5.7%)
Length/height-for-age
(N = 1769)
Mean z-score -1.16 -2.00 -1.72 -0.79 -1.29 -1.17 -0.69 -0.84 -1.29
SD� for z-score 0.98 1.18 1.01 1.00 1.17 0.96 1.34 1.12 1.20
Proportion below 3 SD� 7 (2.3%) 54 (17.4%) 26 (9.0%) 1 (1.1%) 12 (7.1%) 6 (3.7%) 7 (2.9%) 5 (2.5%) 118 (6.7%)
Proportion below 2 SD� 60 (19.5%) 137
(44.2%)
98 (33.9%) 12 (13.2%) 43 (25.4%) 30
(18.5%)
33 (13.8%) 29 (14.4%) 442
(25.0%)
�SD: Standard deviation
https://doi.org/10.1371/journal.pone.0208805.t002
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1000 copies/mL and in 166 VL was >1000 copies/mL. Table 5 also shows that overall, ~14% of
women have not told their partners of their own HIV status–this was especially high in
Uganda (38.6%) and at the two South African sites (20.2% in Soweto and 21.3% in Durban).
The differences in this characteristic across countries were statistically significant (Uganda:
38.6%; Malawi: 3.8%; Zimbabwe: 3.2%; South Africa 20.7%; (p<0.001). Additionally, 72.8% of
women reported that they knew their primary partners were HIV tested; 18.1% reported part-
ner was not HIV tested; and 9.1% reported not knowing if partner was HIV tested.
Table 3. Maternal baseline sociodemographic characteristics by country and research site.
Uganda Malawi Zimbabwe South Africa
Variable MUJHU-Kampala
(N = 352)
Blantyre
(N = 343)
Lilongwe
(N = 322)
Harare
(N = 94)
Seke North
(N = 179)
St. Mary’s
(N = 175)
PHRU-Soweto
(N = 273)
uMlazi-
Durban
(N = 249)
Total
(N = 1987)
Age–years,
Mean (SD)
30.7 (5.4) 30.7 (4.9) 31.2 (5.4) 32.3 (6.2) 32.2 (5.2) 31.6 (5.1) 32.9 (5.5) 30.5 (5.2) 31.4 (5.4)
Marital status, n (%)
�
No regular partner�� 38 (10.8%) 2 (0.6%) 5 (1.6%) 2 (2.1%) 4 (2.2%) 8 (4.6%) 62 (22.7%) 41 (16.5%) 162 (8.2%)
Primary regular partner�� 114 (32.4%) 4 (1.2%) 16 (5.0%) 4 (4.3%) 14 (7.8%) 12 (6.9%) 167 (61.2%) 196 (78.7%) 527 (26.5%)
Married 153 (43.5%) 263
(76.7%)
248
(77.0%)
74 (78.7%) 140
(78.2%)
131
(74.9%)
41 (15.0%) 11 (4.4%) 1061
(53.4%)
Separated 39 (11.1%) 20 (5.8%) 16 (5.0%) 5 (5.3%) 5 (2.8%) 10 (5.7%) 1 (0.4%) 1 (0.4%) 97 (4.9%)
Divorced 0 27 (7.9%) 24 (7.5%) 3 (3.2%) 4 (2.2%) 3 (1.7%) 0 0 61 (3.1%)
Widowed 8 (2.3%) 27 (7.9%) 13 (4.0%) 6 (6.4%) 12 (6.7%) 11 (6.3%) 2 (0.7%) 0 79 (4.0%)
Electricity in the premises,
n (%)
�
275 (78.1%) 192
(56.0%)
89 (27.6%) 55 (58.5%) 122
(68.2%)
113
(64.6%)
264 (96.7%) 242 (97.2%) 1352
(68.0%)
Tap water in the premises,
n (%)
�
149 (42.3%) 244
(71.1%)
137
(42.5%)
55 (58.5%) 114
(63.7%)
107
(61.1%)
272 (99.6%) 224 (90.0%) 1302
(65.5%)
Travel time from home to clinic, n (%) a
�
Less than 30 minutes 19 (5.4%) 43 (12.5%) 22 (6.9%) 42 (44.7%) 107
(59.8%)
69 (39.4%) 100 (36.8%) 94 (37.8%) 496 (25.0%)
30–60 minutes 129 (36.6%) 175
(51.0%)
171
(53.3%)
37 (39.4%) 51 (28.5%) 70 (40.0%) 137 (50.4%) 116 (46.6%) 886 (44.6%)
1–2 hours 136 (38.6%) 101
(29.4%)
101
(31.5%)
14 (14.9%) 17 (9.5%) 27 (15.4%) 32 (11.8%) 31 (12.4%) 459 (23.1%)
Greater than 2 hours 68 (19.3%) 24 (7.0%) 27 (8.4%) 1 (1.1%) 4 (2.2%) 9 (5.1%) 3 (1.1%) 8 (3.2%) 144 (7.3%)
Body mass index (kg/m2)
<18.5 8 (2.3%) 31 (9.0%) 10 (3.1%) 3 (3.2%) 11 (6.1%) 6 (3.4%) 7 (2.6%) 5 (2.0%) 81 (4.1%)
18.5–24.9 164 (46.6%) 194
(56.6%)
190
(59.0%)
49 (52.1%) 80 (44.7%) 98 (56.0%) 73 (26.7%) 81 (32.5%) 929 (46.8%)
25.0–29.9 93 (26.4%) 81 (23.6%) 72 (22.4%) 18 (19.1%) 49 (27.4%) 46 (26.3%) 85 (31.1%) 60 (24.1%) 504 (25.4%)
�30.0 87 (24.7%) 37 (10.8%) 50 (15.5%) 24 (25.5%) 39 (21.8%) 25 (14.3%) 108 (39.6%) 103 (41.4%) 473 (23.8%)
a2 participants had missing data;
� p-value<0.001 calculated from Fisher-Freeman-Halton test;
�� No regular partner: indicates casual partner and Primary regular partner indicates the main co-inhabiting individual identified by the respondent. There were also
differences by site and country for reported reproductive history and contraceptive use as shown in Table 4. Overall, the injectable contraceptive was the commonest
method used (40.9%)–especially at the two South African sites (>55%). The implant was the second commonest method used (15.7%). However, there were variations:
the oral contraceptive was popular at the Zimbabwe sites (40.2%-54.7%) and tubal ligation was common at the Malawi (7.5%-12.9%) and South Africa (7.3%-10.3%)
sites. Other than in Uganda, ~50% or more women reported did not “want to have another child”. The frequency of unplanned immediate prior pregnancy was 29.3%
overall–but very high at the uMlazi/Durban site (52.2%) and low at the Uganda site (9.9%); relatively high at the Malawi sites (>30%).
https://doi.org/10.1371/journal.pone.0208805.t003
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Table 4. Maternal reproductive history by country and research site.
Uganda Malawi Zimbabwe South Africa
Variable MUJHU-Kampala
(N = 352)
Blantyre
(N = 343)
Lilongwe
(N = 322)
Harare
(N = 94)
Seke North
(N = 179)
St. Mary’s
(N = 175)
PHRU-Soweto
(N = 273)
uMlazi-
Durban
(N = 249)
Total
(N = 1987)
Had sex in the last 3 months,
n (%)
257 (73.0%) 249
(72.6%)
227
(70.5%)
74 (78.7%) 148
(82.7%)
140
(80.0%)
187 (68.5%) 183 (73.5%) 1465
(73.7%)
Condoms use, n (%) b
Always 33 (12.8%) 57 (22.9%) 71 (31.3%) 36 (48.6%) 101
(68.2%)
97 (69.3%) 90 (48.4%) 84 (45.9%) 569 (38.9%)
Sometimes 66 (25.7%) 109
(43.8%)
143
(63.0%)
29 (39.2%) 43 (29.1%) 36 (25.7%) 67 (36.0%) 89 (48.6%) 582 (39.8%)
Never 158 (61.5%) 83 (33.3%) 13 (5.7%) 9 (12.2%) 4 (2.7%) 7 (5.0%) 29 (15.6%) 10 (5.5%) 313 (21.4%)
Used family planning methods,
n (%)
169 (74.1%) 194
(85.1%)
199
(93.9%)
53 (74.6%) 127
(92.7%)
115
(91.3%)
138 (78.9%) 174 (97.2%) 1169
(86.2%)
Family planning contraceptive method used (if woman reported sex during past 3 months at baseline)e
Injectables 68 (40.5%) 78 (40.2%) 92 (46.2%) 9 (17.0%) 21 (16.5%) 33 (28.7%) 76 (55.5%) 100 (57.5%) 477 (40.9%)
Condoms 50 (29.8%) 43 (22.2%) 43 (21.6%) 3 (5.7%) 13 (10.2%) 18 (15.7%) 23 (16.8%) 29 (16.7%) 222 (19.0%)
Implant 20 (11.9%) 37 (19.1%) 40 (20.1%) 10 (18.9%) 39 (30.7%) 12 (10.4%) 3 (2.2%) 22 (12.6%) 183 (15.7%)
Oral 19 (11.3%) 2 (1.0%) 4 (2.0%) 29 (54.7%) 51 (40.2%) 51 (44.3%) 21 (15.3%) 3 (1.7%) 180 (15.4%)
Tubal ligation 4 (2.4%) 25 (12.9%) 15 (7.5%) 0 1 (0.8%) 0 10 (7.3%) 18 (10.3%) 73 (6.3%)
Intrauterine contraceptive
device
5 (3.0%) 5 (2.6%) 3 (1.5%) 2 (3.8%) 2 (1.6%) 1 (0.9%) 3 (2.2%) 1 (0.6%) 22 (1.9%)
Withdrawal, herbs or
emergency pill
2 (1.2%) 4 (2.1%) 0 0 0 0 0 0 6 (0.5%)
Hysterectomy 0 0 2 (1.0%) 0 0 0 1 (0.7%) 1 (0.6%) 4 (0.3%)
Currently breastfeeding, n (%)c 30
(8.6%)
41 (12.0%) 49 (15.3%) 15 (16.1%) 26 (14.5%) 26 (14.9%) 5
(1.8%)
3
(1.2%)
195 (9.8%)
Family size desired from the
outset, median(IQR)[min-max]
4 (4–6) [1–18] 3 (3–4) [1–
7]
3 (3–4) [0–
8]
4 (3–4) [0–
10]
4 (3–4) [0–
6]
4 (3–4) [1–
7]
3 (2–4) [0–7] 3 (2–4) [0–
10]
4 (2–4) [0–
18]
Want to have another child, n (%)d
Yes 224 (63.6%) 100
(29.2%)
126
(39.1%)
41 (43.6%) 72 (40.2%) 70 (40.0%) 83 (30.5%) 86 (34.5%) 802 (40.4%)
No 111 (31.5%) 223
(65.0%)
184
(57.1%)
44 (46.8%) 99 (55.3%) 89 (50.9%) 180 (66.2%) 136 (54.6%) 1066
(53.7%)
Not sure 17 (4.8%) 20 (5.8%) 12 (3.7%) 9 (9.6%) 8 (4.5%) 16 (9.1%) 9 (3.3%) 27 (10.8%) 118 (5.9%)
How many more children would
like to have, median (IQR)
1 (1–2) 1 (1–2) 1 (1–1) 1 (1–2) 1 (1–2) 1 (1–2) 1 (1–2) 1 (1–2) 1 (1–2)
Was the last pregnancy planned?, n (%)e
Wanted to be pregnant 251 (71.3%) 167
(48.7%)
137
(42.5%)
66 (70.2%) 104
(58.1%)
104
(59.4%)
120 (44.3%) 45 (18.1%) 994 (50.1%)
Wanted to wait until sometime
later
66 (18.8%) 58 (16.9%) 62 (19.3%) 12 (12.8%) 40 (22.3%) 25 (14.3%) 72 (26.6%) 74 (29.7%) 409 (20.6%)
Did not want to be pregnant 35
(9.9%)
118
(34.4%)
123
(38.2%)
16 (17.0%) 35 (19.6%) 46 (26.3%) 79 (29.2%) 130 (52.2%) 582 (29.3%)
Total pregnancies including
current, median (IQR)
4 (3–5) 3 (3–4) 4 (2–5) 3 (2–4) 3 (2–4) 3 (2–4) 3 (2–4) 3 (2–3) 3 (2–4)
Number children alive today,
median (IQR)
3 (2–4) 3 (2–4) 3 (2–4) 3 (2–3) 3 (2–3 2 (2–3) 2 (1–3) 2 (2–3) 3 (2–3)
b1 with missing data,
c7 with missing data,
d1 with missing data,
https://doi.org/10.1371/journal.pone.0208805.t004
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Discussion
The PROMOTE cohort represents a hybrid example where participants in a highly organized
clinical trial setting are transitioned to a standard of care setting which includes provision of
country-specific ART regimens and clinical care. Therefore, it provides a unique opportunity
to evaluate and assess clinical outcomes which is not possible through country-level service sta-
tistics. Women who enrolled in the PROMOTE study have been receiving counseling and care
for almost five years in a structured clinical setting during the PROMISE trial. Analyses of the
socio-demographic, reproductive and ART findings at enrollment by site and country provide
immediate and important information to assess HIV treatment and prevention in women.
Future studies in PROMOTE will elucidate treatment effects beyond the PROMISE pregnancy
and early postpartum. The PROMOTE data are needed to understand the durability and safety
Table 5. Maternal baseline antiretroviral treatment information by country and research site.
Uganda Malawi Zimbabwe South Africa
Variable MUJHU-Kampala
(N = 352)
Blantyre
(N = 343)
Lilongwe
(N = 322)
Harare
(N = 94)
Seke North
(N = 179)
St. Mary’s
(N = 175)
PHRU-Soweto
(N = 273)
uMlazi-
Durban
(N = 249)
Total
(N = 1987)
Currently taking ARV
treatment,
n (%) ���
348
(98.9%)
335
(97.7%)
308
(95.7%)
91 (96.8%) 177
(98.9%)
174
(99.4%)
264 (96.7%) 247
(99.2%)
1944
(97.8%)
WHO clinical classification, n (%)f
1 239 (69.1%) 319
(93.3%)
302
(94.4%)
84 (90.3%) 137
(76.5%)
159
(91.9%)
261 (99.6%) 211 (86.1%) 1712
(87.3%)
2 88 (25.4%) 11 (3.2%) 10 (3.1%) 8 (8.6%) 29 (16.2%) 11 (6.4%) 0 22 (9.0%) 179 (9.1%)
3 16 (4.6%) 8 (2.3%) 7 (2.2%) 1 (1.1%) 12 (6.7%) 3 (1.7%) 0 10 (4.1%) 57 (2.9%)
4 3 (0.9%) 4 (1.2%) 1 (0.3%) 0 1 (0.6%) 0 1 (0.4%) 2 (0.8%) 12 (0.6%)
Viral load, copies/mL, n (%)g
>1000 25 (7.1%) 38 (12.5%) 52 (16.3%) 6 (6.4%) 8 (4.5%) 17 (9.7%) 8 (3.0%) 12 (5.2%) 166 (8.6%)
400–1000 4 (1.1%) 6 (2.0%) 9 (2.8%) 3 (3.2%) 1 (0.6%) 3 (1.7%) 3 (1.1%) 3 (1.3%) 32 (1.7%)
200–399 4 (1.1%) 2 (0.7%) 3 (0.9%) 1 (1.1%) 3 (1.7%) 0 1 (0.4%) 3 (1.3%) 17 (0.9%)
<200 28 (8.0%) 8 (2.6%) 10 (3.1%) 4 (4.3%) 5 (2.8%) 4 (2.3%) 8 (3.0%) 10 (4.3%) 77 (4.0%)
Undetectable 291 (82.7%) 251
(82.3%)
246
(76.9%)
80 (85.1%) 162
(90.5%)
151
(86.3%)
251 (92.6%) 205 (88.0%) 1637
(84.9%)
CD4 count (cells/uL),
median (IQR)��
963.5
(747 –
1189.5)
764
(593 –
965)
727
(545 –
904)
959.5 (779–
1170)
928
(761–
1069)
858
(646–
1081)
727
(601 –
880)
886
(721.5–
1083.5)
825
(647 –
1035)
Disclosed HIV status to
primary partner,
n (%) †
164 (61.4%) 253
(94.8%)
258
(97.7%)
77 (98.7%) 148
(96.1%)
138
(96.5%)
166 (79.8%) 163 (78.7%) 1367
(86.1%)
Has partner been tested for HIV, n (%)†
Yes 155 (58.1%) 203
(76.0%)
213
(80.7%)
66 (84.6%) 124
(80.5%)
115
(80.4%)
146 (70.2%) 134 (64.7%) 1156
(72.8%)
No 23 (8.6%) 61 (22.8%) 42 (15.9%) 10 (12.8%) 27 (17.5%) 24 (16.8%) 45 (21.6%) 56 (27.1%) 288 (18.1%)
Don’t know 89 (33.3%) 3 (1.1%) 9 (3.4%) 2 (2.6%) 3 (1.9%) 4 (2.8%) 17 (8.2%) 17 (8.2%) 144 (9.1%)
f27 missing data,
g 58 missing data,
† among 1588 who had partners,
�p-value<0.001 calculated from Fisher-Freeman-Halton test;
��p-value <0.001 from Kruskal-Wallis test,
��� 85.0% on efavirenz-based regimen (>95% at all sites >95% other than MUJHU, Kampala site (~30%)) and 15.0% on protease inhibitor-based regimen (all site <5%
other than MUJHU, Kampala site (69%)).
https://doi.org/10.1371/journal.pone.0208805.t005
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of universal ART and monitor trends in behaviors such as fertility decisions after prolonged
use of ART [10, 11].
The overall achievements relating to ART use are encouraging and consistent with what
was observed earlier in this cohort of healthy women for prevention of HIV transmission dur-
ing pregnancy and postpartum (~0.5% perinatal transmission [1, 2]). The PROMOTE baseline
data show that 98% of the women are continuing to use ART and ~85% had undetectable
virus in blood samples (with high CD4 cell counts and lack of advanced HIV clinical disease)
suggesting high adherence. These findings are consistent with data from the PHIA surveys
conducted in Malawi, Zimbabwe and Zambia where 87% who knew their HIV status were on
ART and 89% had viral suppression below 1000 copies/mL (4) as well as earlier data from
other African settings [12,13].
Nonetheless, few baseline findings from this study raise concerns. For example, despite
years of counseling on HIV during the PROMISE study, 14% of the women (higher in
Uganda and South African sites) did not inform their primary partners about their HIV sta-
tus, and 9% of the women reported not knowing if their partners were HIV tested. Some of
the socioeconomic and reproductive characteristics of this cohort of HIV-infected women
may explain these inadequacies–and highlight the difficulties that health care providers are
facing in these countries. Although variable across site, there were substantial differences in
marital status; only 53% of women reported being married—these were mostly in Malawi
and Zimbabwe. The frequency of not having regular partnership was high in the South Afri-
can sites and Uganda. The frequency of nonuse of contraception methods was also high at
some sites. A more striking finding in this baseline evaluation (and a prominent emerging
concern during the on-going follow-up) is the high frequency of subsequent pregnancies–
suggesting changes in fertility whether desired or unplanned. At some sites, more than 40%
of women wanted to be pregnant and the frequency of unwanted pregnancy was high.
These same factors have been well-described in early studies of HIV infection in sub-Saha-
ran Africa [14–18]. What is currently emerging is likely the effect of ART and the new
expectation and desires of these women. It is expected that consistent use of ART will mini-
mize HIV transmission. However, repeat pregnancies at short intervals can impact infant
and maternal health independent of HIV and ART use [19]. In the era of universal ART use,
strategies that maximize maternal health should be addressed at the individual, couples and
health care provider levels.
A major strength of this study is the large sample size obtained from multiple sites and
countries allowing for generalizability of the findings. Although current data are only from the
baseline enrollment visit, it should be realized that these women and children have been under
follow-up for several years. Therefore, assessment of previous interventions such as mainte-
nance of ART adherence and counseling on HIV prevention will be examined in future stud-
ies. A potential limitation of the current analysis is its cross-sectional nature; however, future
analyses will build on these baseline findings and provide longitudinal assessments.
Despite the global successes in prevention and treatment of HIV and acknowledging vari-
ability between sites and countries, these data from sub-Saharan Africa reveal some important
policy challenges. Better approaches are needed to address and manage some chronic con-
straints such as gender power imbalances and inadequate socio-economic situations [20–23].
Additionally, more work is needed in some essential prevention approaches. ART is well
accepted and there are definite improvements in maternal health—but how to overcome the
barriers that are entangled with cultural and societal norms such as the desire for more chil-
dren and the continued high fertility? The success of ART should provide a venue to address
the reproductive health needs of these women; e.g., emphasis on the appropriate spacing of the
inter-pregnancy interval through use and making available safe contraceptive approaches.
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Building on these baseline data, future PROMOTE reports will focus on long-term safety,
adherence to different ART regimens, progression of HIV disease and survival of mothers and
children.
Disclaimer
The findings and conclusions reported herein are those of the author(s) and do not necessarily
reflect the official position of the U.S. government.
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